July 2011
905
ported by the HMBC experiment for 5, long-range correla-
tions between H-26 (dH 3.95) and C-24 (dC 217.7), H-27 (dH
1.49) and C-24, and C-25 (dC 80.0) and C-26 (dC 69.2) being
observed. The absolute configuration of the newly formed
chiral center remains to be determined. Therefore, the struc-
(Inertsil; GL Science, Tokyo, Japan; Fꢁ20 mm, Lꢁ25 cm, flow rate
4 ml/min) with 70% MeOH to afford 5.83 mg of 5 from the peak at 23.5 min.
The residue (65.8 mg in fractions 88—106) of the eluate obtained on DCCC
was purified by HPLC with 60% MeOH to afford 21.1 mg of 1 from the
peak at 9 min.
Tarecilioside H (1): Amorphous powder; [a]D25 ꢀ15.5 (cꢁ0.73, pyridine);
1
ture of tarecilioside L (5) was tentatively elucidated to be 26- IR nmax (film) cmꢀ1: 3408, 2971, 1457, 1376, 1368, 1068, 1050; H-NMR
(400 MHz, pyridine-d5) and 13C-NMR (100 MHz, pyridine-d5): Tables 1 and
hydroxytarecilioside K.
2, respectively; HR-ESI-MS (positive-ion mode) m/z: 823.4825 [MꢅNa]ꢅ
Tarecilioside M (6), [a]D25 ꢀ32.9, was isolated as an amor-
(Calcd for C42H72O14Na: 823.4814).
phous powder and its molecular formula was determined to
be C48H78O20 on positive-ion HR-ESI-TOF-MS. Tarecilioside
M (6) was also a cycloartane triglycoside analogous to tare-
cilioside K (4). The difference between the 13C-NMR spectra
of 6 and 4 was that one more highly deshielded signal was
observed at dC 219.9 which was expected to represent one
more isolated ketone functional group that was located at C-
16, judging from the cross peaks between H2-15 (dH 2.66,
2.72) and H-17 (dH 2.35), and C-16 (dC 219.9) in the HMBC
spectrum. Therefore the structure of tarecilioside M (6) was
tentatively elucidated to be 16-ketotarecilioside K.
Tarecilioside I (2): Amorphous powder; [a]D25 ꢀ10.3 (cꢁ0.77, pyridine);
1
IR nmax (film) cmꢀ1: 3367, 2937, 1592, 1443, 1380, 1070, 1043; H-NMR
(400 MHz, pyridine-d5) and 13C-NMR (100 MHz, pyridine-d5): Tables 1 and
2, respectively; HR-ESI-MS (positive-mode) m/z: 955.5243 [MꢅNa]ꢅ
(Calcd for C47H80O18Na: 955.5236).
Tarecilioside J (3): Amorphous powder; [a]D25 ꢀ18.8 (cꢁ0.22, pyridine);
1
IR nmax (film) cmꢀ1: 3367, 2936, 1704, 1455, 1380, 1074, 1045; H-NMR
(400 MHz, pyridine-d5) and 13C-NMR (100 MHz, pyridine-d5): Tables 1 and
2, respectively; HR-ESI-MS (positive-mode) m/z: 983.5177 [MꢅNa]ꢅ
(Calcd for C48H80O19Na: 983.5186).
Tarecilioside K (4): Amorphous powder; [a]D25 ꢀ5.96 (cꢁ0.75, pyridine);
1
IR nmax (film) cmꢀ1: 3367, 2937, 1701, 1457, 1377, 1075, 1028; H-NMR
(600 MHz, pyridine-d5) and 13C-NMR (150 MHz, pyridine-d5): Tables 1 and
2, respectively; HR-ESI-MS (positive-mode) m/z: 999.5153 [MꢅNa]ꢅ
(Calcd for C48H80O20Na: 999.5135).
Experimental
Tarecilioside L (5): Amorphous powder; [a]D25 ꢅ1.19 (cꢁ0.17, pyridine);
General Experimental Procedures IR spectra were obtained on a
Horiba Fourier transform infrared spectrophotometer FT-710. Optical rota-
tion data were measured on a JASCO P-1030 polarimeter. 1H- and 13C-NMR
spectra were recorded on a JEOL JNM a-400 spectrometer at 400 MHz and
100 MHz, and a JEOL ECA-600 spectrometer at 600 MHz and 150 MHz, re-
spectively, with tetramethylsilane as an internal standard. Positive-ion HR-
ESI-TOF-MS was performed with an Applied Biosystems QSTAR® XL
NanoSpray System.
1
IR nmax (film) cmꢀ1: 3367, 2935, 1702, 1456, 1380, 1074, 1029; H-NMR
(400 MHz, pyridine-d5) and 13C-NMR (100 MHz, pyridine-d5): Tables 1 and
2, respectively; HR-ESI-MS (positive-ion mode) m/z: 999.5141 [MꢅNa]ꢅ
(Calcd for C48H80O20Na: 999.5135).
Tarecilioside M (6): Amorphous powder; [a]D25 ꢀ32.9 (cꢁ0.26, pyridine);
1
IR nmax (film) cmꢀ1: 3376, 2936, 1716, 1457, 1381, 1075, 1028; H-NMR
(400 MHz, pyridine-d5) and 13C-NMR (100 MHz, pyridine-d5): Tables 1 and
2, respectively; HR-ESI-MS (positive-ion mode) m/z: 997.4966 [MꢅNa]ꢅ
(Calcd for C48H78O20Na: 997.4978).
Highly-porous synthetic resin Diaion HP-20 (Fꢁ60 mm, Lꢁ65 cm) was
purchased from Mitsubishi Chemical Co., Ltd. (Tokyo, Japan). Silica gel CC
was performed on silica gel 60 [E. Merck, Darmstadt, Germany, 70—230
mesh]. Reversed-phase [octadecyl silica gel (ODS)] open CC (RPCC) was
performed on Cosmosil 75C18-OPN (Nacalai Tesque, Kyoto, Japan) [Fꢁ
50 mm, Lꢁ25 cm, linear gradient: MeOH–H2O (1 : 9, 1.5 l)→(7 : 3, 1.5 l),
10 g fractions being collected]. DCCC (Tokyo Rikakikai, Tokyo, Japan) was
equipped with 500 glass columns (Fꢁ2 mm, Lꢁ40 cm), and the lower and
Analyses of the Sugar Moiety About 1 mg each of tareciliosides H—M
(1—6) was hydrolyzed with 1 M HCl (0.1 ml) at 90 °C for 2 h. The reaction
mixtures were partitioned with an equal amount of EtOAc (0.1 ml), and the
water layers were analyzed with a chiral detector (JASCO OR-2090plus) on
an amino column [Asahipak NH2P-504E, CH3CN–H2O (4 : 1), 1 ml/min].
Tareciliosides H (1) and J (3) gave peaks for L-rhamnose and D-glucose at
the retention times of 5.5 min (negative optical rotation sign) and 8.5 min
(positive optical rotation sign), respectively, tarecilioside I (2) gave peaks for
L-rhamnose, D-xylose and D-glucose at the retention times of 5.5 min (nega-
tive optical rotation sign), 6.7 min (positive optical rotation sign), and
8.5 min (positive optical rotation sign), respectively, and tareciliosides K (4),
L (5) and M (6) each gave a peak for D-glucose at the retention time at
8.5 min (positive optical rotation sign), respectively. Peaks were identified by
co-chromatography with anthentic L-rhamnose, D-xylose and D-glucose.
upper layers of
a solvent mixture of CHCl3–MeOH–H2O–1-PrOH
(9 : 12 : 8 : 2) were used as the mobile and stationary phases, respectively.
Five grams fractions were collected and numbered according to their order
of elution with the mobile phase. HPLC was performed on an ODS (Inertsil;
GL Science, Tokyo, Japan; Fꢁ6 mm, Lꢁ25 cm, flow rate 1.6 ml/min) col-
umn. Precoated silica gel 60 F254 TLC plates (E. Merck; 0.25 mm in thick-
ness) were used for identification.
Plant Material Leaves of T. gracilipes (HAYATA) OHWI were collected in
Okinawa, Japan, in July 2002, and a voucher specimen was deposited in the
Herbarium of Pharmaceutical Sciences, Graduate School of Biomedical Sci-
ences, Hiroshima University (02-TG-Okinawa-0705).
Extraction and Isolation The 1-BuOH-soluble fraction (149 g) of a
MeOH extract of dried leaves (9.9 kg) of T. gracilipes1) was subjected to
highly porous synthetic resin (Diaion HP-20) CC (Fꢁ60 mm, Lꢁ65 cm),
using a stepwise-gradient of MeOH–H2O [(1 : 4, 6 l), (2 : 3, 6 l), (3 : 2, 6 l),
(4 : 1, 6 l), and MeOH (6 l)], 500 ml fractions being collected. The residue
eluted with the 60—80% MeOH (29.6 g in fractions 14—19) eluate obtained
on HP-20 CC was subjected to silica gel (500 g) CC using CHCl3 (3 l),
CHCl3–MeOH [(99 : 1, 3 l), (97 : 3, 3 l), (19 : 1, 3 l), (37 : 3, 3 l), (9 : 1, 6 l),
(7 : 17, 3 l), (17 : 3, 3 l), (33 : 7, 3 l), (4 : 1, 3 l), (3 : 1, 3 l) (7 : 3, 3 l)] and
CHCl3–MeOH–H2O (35 : 15 : 2, 3 l), fractions of 500 ml being collected. The
residue (2.51 g in fractions 59—65) of the 25% MeOH in CHCl3 eluate ob-
tained on silica gel CC was subjected to PRCC. The residue (370 mg in frac-
tions 205—219) was separated by DCCC and then the residue (52.4 mg in
fractions 62—72) was separated by HPLC with 65% MeOH to give 7.77 mg
of 6 from the peak at 28 min. The residue (480 mg in fractions 220—240)
was separated by DCCC to give 323 mg of 4 in fractions 51—66. The
residue (302 mg in fractions 241—265) was separated by DCCC. The
residue (44.8 mg in fractions 43—53) of the eluate obtained on DCCC was
purified by HPLC with 60% MeOH to afford 6.30 mg of 3 from the peak at
6 min, and 14.6 mg of 2 from the peak at 22.4 min. The residue (62.9 mg in
fractions 54—74) of the eluate obtained on DCCC was purified by HPLC
Acknowledgements The authors are grateful for access to the supercon-
ducting NMR instrument (JEOL JNM a-400) at the Analytical Center of
Molecular Medicine of the Hiroshima University Faculty of Medicine and
an Applied Biosystem QSTAR XL system ESI (Nano Spray)-TOF-MS at the
Analysis Center of Life Science of the Graduate School of Biomedical Sci-
ences, Hiroshima University. The authors are also grateful for the use of the
NMR instrument (JEOL ECA-600) at the Natural Science Center for Basic
Research and Development, Hiroshima University. This work was supported
in part by Grants-in-Aid from the Ministry of Education, Culture, Sports,
Science and Technology of Japan, the Japan Society for the Promotion of
Science, and the Ministry of Health, Labour and Welfare. Thanks are also
due to the Research Foundation for Pharmaceutical Sciences and the Takeda
Science Foundation for the financial support.
References
1) Zhao Z., Matsunami K., Otsuka H. Shinzato T., Takeda Y., Chem.
Pharm. Bull., 56, 1153—1158 (2008).
2) Kucherbaev K. D., Uteniyazov K. K., Saatov Z., Shashkov A. S.,
Chem. Nat. Compd., 38, 447—449 (2002).
3) Özipek M., Dönmez A. A. Çalis¸ Ì., Brun R., Rüed P., Tasdemir D.,
Phytochemistry, 66, 1168—1173 (2005).